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maximal postdilation pressure: 16.05  4.24mmhg). Baseline clinical
characteristics were similar between the PD and non-PD groups. The
left anterior descending artery (47.8%) was the most commonly
treated vessel in the study population. Lesion complexity and calci-
ﬁcation were higher in the PD group (AHA B2/C lesion: 48.4% in PD vs
24.5% in non-PD, p < 0.001; Moderate/heavy calciﬁcation: 51.2% vs
29.6%, p<0.001). Treatment length was signiﬁcantly longer in PD
compared to non-PD (25.31 14.53 vs 20.06 10.13, p<0.001). Lesion
preparation (percentage predilation performed and pre B:A ratio) was
similar between the PD and non-PD groups. Acute lumen gain was
signiﬁcantly decreased in PD compared to non-PD (1.33 0.59 vs 1.53
0.63mm, p¼ 0.002). From QCA, PD resulted in a signiﬁcant increase
in reference vessel diameter (RVD, 0.16  0.37, p< 0.001), minimal
lumen diameter (MLD: 0.14  0.32mm, p < 0.001) and non-signiﬁcant
decrease in diameter stenosis [%DS: (-)0.03  12.39%, p¼ 0.976] after
BRS implantation. Overall device success rates was 99.5% and all-
cause mortality occurred in 2.7% of the study population with no
differences between the PD and non-PD groups. Other clinical out-
comes are currently being adjudicated and would be available on
presentation.
CONCLUSIONS In our study, while PD resulted in a marginal increase
in RVD and MLD after BRS implantation, acute lumen gain was smaller
in the PD group and short term procedural outcome and mortality
remained similar between the 2 groups.
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BACKGROUND No reports have described the ultrastructural changes
that occur over the course of bioresorption of the everolimus-eluting
Absorb BVS (150 mm PLLA-strut thickness with 6 mm PDLLA-coating)
[Abbott Vascular, Santa Clara, CA].
METHODS Eighteen Absorb BVS were implanted in main coronary
arteries of healthy Yucatan mini Swine. Transmission electron mi-
croscopy was performed at seven time points from 28-days to 48-
months. Ultrastructural changes of polymeric struts / resorption sites
(RS, > 36 months) were morphologically characterized.
RESULTS Up to 12-months, struts were intact with surrounding
macrophages and ﬁbroblasts. The PDLLA polymer coating was
observed as a black line of calciﬁed material (A) as thinly separated
from the strut polymer. Collagen deposition was seen along the sur-
faces with acellular cytoplasmic processes extending into the strut
surface from the surrounding cellular area (B & C). At 24-months the
acellular processes extended deeper into the strut surface. Collagen
and smooth muscle cells bordered the strut. At 30-months, some strut
surfaces remained intact with surrounding dense collagen and ﬁbro-
blasts (B) while other areas shows superﬁcial polymer micro-
fragmentation (A & C). Internally, struts appeared sparsely granular.
At 36-months RS were tightly surrounded by ﬁbrous tissue (B).
Cellular and collagen-proteoglycan ingrowth subdivided RS, which
show more dense granularity than at 30 months (A & C). At 42- and 48-
months, RS were reduced to multiple amorphous, densely granular
particles subdivided and surrounded by collagen and proteoglycan
rich matrix with myoﬁbroblasts and interspersed calciﬁed material.CONCLUSIONS Our investigation reveals the nature of the changes
seen within the polymeric struts. As polymer resorbs (30 - 36 months)
it shows increasing granularity (nonﬁbrellar glycoprotein) with
eventual replacement by a proteinceous matrix with integrated
collagen and myoﬁbroblasts at 48-months.
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BACKGROUND The data concerning the use of bioresorbable vascular
scaffolds (BVS) in coronary bifurcation lesions are limited. Given the
complexity of the procedure and the potential risk of struts’ damage it
is imperative to evaluate the efﬁcacy and long-term safety of BVS in
such lesions. The aim of the study was to evaluate the early and long-
term clinical outcomes of bifurcation stenting with BVS.
METHODS The study is a prospective, nonrandomized clinical registry
of patients with coronary bifurcation lesion treated with everolimus-
eluting BVS. Sixty consecutive patients, with stable coronary artery
disease or acute coronary syndromes were enrolled. The study
excluded patients with concomitant serious illnesses, those who were
unable to receive prolonged dual antiplatelet therapy or required
chronic oral anticoagulation therapy. Bifurcation lesion was deﬁned
and classiﬁed according to European Bifurcation Club deﬁnition and
Medina classiﬁcation. The main clinical study end point was a device-
oriented target lesion failure (TLF), deﬁned as the combination of
cardiac death, target vessel myocardial infarction, or clinically driven
target lesion revascularization.
RESULTS Sixty consecutive patients (male 71.7%, mean age 62.611.2
years) were included, 18 of them had diabetes mellitus (30%) and 10
chronic kidney disease (17%). True bifurcation lesion was found in 27
patients (45%). Nine lesions (15%) comprised the left main coronary
artery. On QCA the mean proximal and distal main vessel reference
diameters were 3.12  0.36 mm and 2.65  0.43 mm respectively,
whereas the mean lesion length and diameter stenosis were 12.73 
9.53 mm and 69.72  27.33 mm. The mean side branch (SB) reference
diameter was 2.34  0.36 mm, SB lesion length 5.66  5.27 mm, and
lesion diameter stenosis 44.58 27.47%. A total of 71 BVS were
implanted. Provisional T stenting was performed in 42 patients (70%),
distal main vessel stenting in one patient, systematic T stenting in 6
(10%), and T with minimal protrusion (TAP) in 2 patients (2.2%). SB
ostial stenting was performed in additional 9 patients (15%). The ﬁnal
